文献速递浆细胞疾病造血干细胞移植与细胞治疗

原发浆细胞白血病首次进展后的进展模式与临床结局

Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia.
PubMed 文献 · Am J Hematol · 2026-06-03

该回顾性研究分析了2006至2024年间单中心104例一线治疗后进展的原发浆细胞白血病(pPCL)患者,中位总生存39个月,中位首次后续治疗时间10个月。症状性进展者后续生存显著差于无症状生化进展者,后续治疗线数增加则缓解持续时间递减,t(11;14)患者接受抗BCL-2治疗及抗BCMA CAR-T治疗显示更持久疾病控制。

要点

  • pPCL首次进展后中位总生存39个月,高危细胞遗传学占71%。
  • 症状性进展者后续中位OS仅13个月,显著差于无症状生化进展者的34个月。
  • 后续治疗线数增加,中位至下次治疗时间逐线缩短:三线6个月、四线4个月、五线3个月。

核心结论

  • pPCL首次进展后疾病进展频繁,随治疗线数增加缓解持续时间递减。
  • 症状性进展预示尤其差的结局。
  • t(11;14)疾病使用抗BCL-2方案及抗BCMA CAR-T治疗可提供更持久疾病控制。

研究设计与样本

  • 单中心回顾性分析2006至2024年间104例一线治疗后进展的pPCL患者。
  • 所有患者均接受含新型药物的诱导治疗。
  • 采用Kaplan-Meier法评估至下次治疗时间(TTNT)和总生存(OS)。

主要发现

  • 分析时63%患者死亡,中位OS为39个月,高危细胞遗传学占71%。
  • 一线治疗后中位TTNT为10个月。
  • 症状性进展占29%,其后继OS为13个月,无症状生化进展者为34个月。
  • 后续治疗中位TTNT:三线6个月、四线4个月、五线3个月。
  • t(11;14)患者接受抗BCL-2方案中位TTNT为13个月;24例接受抗BCMA CAR-T治疗者中位随访21个月,中位TTNT为32个月。

临床怎么用

  • pPCL进展后应关注进展类型,症状性进展者需积极干预并密切监测。
  • 对t(11;14)的pPCL患者可考虑抗BCL-2为基础的方案。
  • 抗BCMA CAR-T细胞治疗可作为进展后pPCL的重要治疗选择。

局限性

  • 单中心回顾性研究设计。
  • 样本量104例,抗BCMA CAR-T亚组仅24例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary plasma cell leukemia (pPCL) is a rare and aggressive plasma cell disorder with inferior outcomes compared with multiple myeloma (MM). However, studies describing outcomes after first progression and subsequent lines of therapy remain limited. We retrospectively analyzed 104 patients with pPCL who progressed after first-line therapy treated at one comprehensive cancer center between 2006 and 2024. Clinical characteristics, treatments, time to next treatment (TTNT), and overall survival (OS) were assessed using Kaplan-Meier methods. All pPCL patients received novel agent-based induction. At the time of analysis, 63% had died; median OS was 39 months. High-risk cytogenetics were present in 71%. The median TTNT after first-line therapy was 10 months. Symptomatic progression occurred in 29% of patients and was associated with significantly inferior subsequent OS (13 vs. 34 months) compared with those experiencing asymptomatic biochemical progression. The TTNT progressively shortened with subsequent lines of therapy (3rd line: 6 months; 4th line: 4 months; 5th line: 3 months). Notable exceptions included pPCL patients with t(11;14) treated with anti-BCL-2-based regimens, who achieved a median TTNT of 13 months. Additionally, 24 patients received anti-BCMA CAR T-cell therapy. With a median follow-up of 21 months, their median TTNT was 32 months. pPCL is characterized by frequent disease progression and diminishing response duration with successive therapeutic lines. Symptomatic progression portends particularly poor outcomes. Anti-BCL-2-based therapy in t(11;14) disease and anti-BCMA CAR T-cell therapy appear to provide more durable disease control and represent important advances for the management of progressed pPCL.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Packard DG, Kumar SK, Dispenzieri A, et al. Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia. Am J Hematol. 2026. PMID: 42237452. doi:10.1002/ajh.70400

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。